{
  "docId": "019de074-5234-763a-a0be-96f5f1aa05d9",
  "docSlug": "9279d19020d2e95032dc34a127aaa2e7",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 40,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "MTD = Maximum Tolerated Dose; PR = Partial Response; RECIST = Response Evaluation Criteria in Solid Tumors; ORR = Objective Response Rate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-5234-763a-a0be-96f5f1aa05d9/9",
  "deckHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9",
  "deckJsonHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9.json",
  "deckAnchorHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.25,
        "x": 0.03,
        "y": 0.66
      },
      "kind": "callout",
      "text": "Phase 1 Results",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c25173d5-2fa1-41a0-af89-aaf272bd436c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "list",
      "text": "Safety: well-tolerated; MTD has not been determined\nActivity: 8 PRs, 6 confirmed by RECIST in 33 advanced solid tumor patients treated\nResponses as a monotherapy: colorectal and gastric\nResponses in combination with chemotherapy: cholangiocarcinoma, pancreatic\nCholangio ORR= 50%; Clinical benefit rate = 75% with a median duration of response of 9.7 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3c7fbfe-4191-47ae-810a-a7b7e180ea2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "list",
      "text": "N=45: Gastric, CRC, Other\nNine dose-escalation cohorts (0.3-17.5 mg/kg)\nFour dose-expansion cohorts (7.5-15 mg/kg)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d073419c-823e-483f-9f3b-87878e0832f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.52,
        "y": 0.32
      },
      "kind": "list",
      "text": "N=17: 4 arms\n1. CTX-009 10.0 mg/kg + paclitaxel\n2. CTX-009 10.0 mg/kg + irinotecan\n3. CTX-009 12.5 mg/kg + paclitaxel\n4. CTX-009 12.5 mg/kg + irinotecan",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f09223b-2316-47ec-b6c3-945de68b33a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.43,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "paragraph",
      "text": "Phase 1a: dose-escalation monotherapy study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7250fa76-e479-4d01-8c97-9cf6cea1ce84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.43,
        "x": 0.51,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Phase 1b: combination study with chemotherapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80e00fd0-0f1f-44d0-9bee-ad562500d217",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "CTX-009 Phase 1 Program Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bad72e5-1d21-47cb-a7ae-2e3206203969",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "d5e03937-35e0-480b-9c15-3a456dbe1e6a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents an overview of CTX-009, CTX-471, and CTX-8371, including their potential benefits and development plans.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f0a32b3c-a238-480c-9a9d-c05166154467",
      "evidence": "The document implies that the current state of cancer treatment is inadequate and that innovative therapies are needed.",
      "position": 0,
      "objective": "The cost of inaction in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "6979bcd9-f71b-4757-b297-1c4753563587",
      "evidence": "The document presents data and results for each of these therapies.",
      "position": 1,
      "objective": "The potential benefits of CTX-009, CTX-471, and CTX-8371",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}